Literature DB >> 21163325

Functional recovery after severe CNS trauma: current perspectives for cell therapy with bone marrow stromal cells.

Jesús Vaquero1, Mercedes Zurita.   

Abstract

The aim of this paper is to identify current perspectives for cell therapy applied to traumatic injuries of the central nervous system (CNS). After using diverse types of cell therapy, at present there is a growing experimental evidence that transplantation of bone marrow stromal cells (BMSC) can be useful to reverse the sequels of trauma affecting the brain and spinal cord. Although we still do not know many details about how these cells achieve their beneficial effects, the application of BMSC in humans, for brain or spinal cord repair, is beginning. An exquisite caution and strict methodological controls are needed to determine with certainty whether we can open a door of hope for many patients who currently suffer severe neurological deficits that are now supposedly irreversible.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21163325     DOI: 10.1016/j.pneurobio.2010.12.002

Source DB:  PubMed          Journal:  Prog Neurobiol        ISSN: 0301-0082            Impact factor:   11.685


  15 in total

Review 1.  Concise Review: Prospects of Bone Marrow Mononuclear Cells and Mesenchymal Stem Cells for Treating Status Epilepticus and Chronic Epilepsy.

Authors:  Satish Agadi; Ashok K Shetty
Journal:  Stem Cells       Date:  2015-05-13       Impact factor: 6.277

2.  Stem cells in regenerative medicine.

Authors:  Eva Sykova; Serhiy Forostyak
Journal:  Laser Ther       Date:  2013-03-31

Review 3.  Response of the cerebral vasculature following traumatic brain injury.

Authors:  Arjang Salehi; John H Zhang; Andre Obenaus
Journal:  J Cereb Blood Flow Metab       Date:  2017-04-05       Impact factor: 6.200

4.  Bone Marrow Stromal Cell Intraspinal Transplants Fail to Improve Motor Outcomes in a Severe Model of Spinal Cord Injury.

Authors:  John H Brock; Lori Graham; Eileen Staufenberg; Eileen Collyer; Jacob Koffler; Mark H Tuszynski
Journal:  J Neurotrauma       Date:  2015-11-13       Impact factor: 5.269

5.  Therapeutic effects of human multilineage-differentiating stress enduring (MUSE) cell transplantation into infarct brain of mice.

Authors:  Tomohiro Yamauchi; Yasumasa Kuroda; Takahiro Morita; Hideo Shichinohe; Kiyohiro Houkin; Mari Dezawa; Satoshi Kuroda
Journal:  PLoS One       Date:  2015-03-06       Impact factor: 3.240

6.  L-serine treatment may improve neurorestoration of rats after permanent focal cerebral ischemia potentially through improvement of neurorepair.

Authors:  Li Sun; Ren Qiang; Yao Yang; Zheng-Lin Jiang; Guo-Hua Wang; Guang-Wei Zhao; Tao-Jie Ren; Rui Jiang; Li-Hua Xu
Journal:  PLoS One       Date:  2014-03-26       Impact factor: 3.240

Review 7.  Myelin damage and repair in pathologic CNS: challenges and prospects.

Authors:  Arsalan Alizadeh; Scott M Dyck; Soheila Karimi-Abdolrezaee
Journal:  Front Mol Neurosci       Date:  2015-07-27       Impact factor: 5.639

8.  The Morphofunctional Effect of the Transplantation of Bone Marrow Stromal Cells and Predegenerated Peripheral Nerve in Chronic Paraplegic Rat Model via Spinal Cord Transection.

Authors:  Vinnitsa Buzoianu-Anguiano; Sandra Orozco-Suárez; Elisa García-Vences; Sara Caballero-Chacón; Gabriel Guizar-Sahagún; Luis Chavez-Sanchez; Israel Grijalva
Journal:  Neural Plast       Date:  2015-11-08       Impact factor: 3.599

9.  Chondroitinase ABC plus bone marrow mesenchymal stem cells for repair of spinal cord injury.

Authors:  Chun Zhang; Xijing He; Haopeng Li; Guoyu Wang
Journal:  Neural Regen Res       Date:  2013-04-15       Impact factor: 5.135

10.  Intravenous transplantation of bone marrow mesenchymal stem cells promotes neural regeneration after traumatic brain injury.

Authors:  Fatemeh Anbari; Mohammad Ali Khalili; Ahmad Reza Bahrami; Arezoo Khoradmehr; Fatemeh Sadeghian; Farzaneh Fesahat; Ali Nabi
Journal:  Neural Regen Res       Date:  2014-05-01       Impact factor: 5.135

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.